世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 DNA Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for DNA Vaccines was estimated to be worth US$ 5378 million in 2024 and is forecast to a readjusted size of US$ 8975 million by 2031 with a CAGR of 7.7% during the forecast period... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global market for DNA Vaccines was estimated to be worth US$ 5378 million in 2024 and is forecast to a readjusted size of US$ 8975 million by 2031 with a CAGR of 7.7% during the forecast period 2025-2031.DNA vaccines are vaccines that use recombinant DNA technology, introducing plasmids or other DNA vectors encoding specific antigens of a pathogen into the host organism, where host cells transcribe and translate the antigen, thus eliciting a specific immune response. Compared to traditional inactivated or attenuated vaccines, DNA vaccines offer flexibility in design, shorter production cycles, relatively high safety, and no risk of transmission of the complete pathogen. They are particularly promising in prevention of infectious diseases, tumor immunotherapy, and rapid response to public health threats, thanks to their capability for rapid customization, large-scale production, and comparatively easier storage, making them a key focus for global biopharma companies, governments, and research institutions. Amid growing global public health needs, frequent emergence of infectious disease variants, rising cancer incidence, and escalating antimicrobial resistance, DNA vaccines are increasingly viewed as core next-generation vaccine and immunotherapy solutions. Governments and international agencies have significantly increased funding for research targeting emerging pathogens (such as coronaviruses, malaria, dengue etc.), thereby providing continuous policy and financial support for DNA vaccine projects. At the same time, leaps in synthetic biology, gene synthesis, plasmid design and immunogenicity optimization have shortened timelines from lab validation to clinical stages, reducing failure costs. In clinical trials, multiple DNA vaccine candidates have shown positive safety profiles and immune responses (including T cell responses), boosting the confidence of markets and investors. Moreover, demand in the animal health / veterinary vaccine sector continues to accelerate, as viral and parasitic diseases exact heavy losses in livestock/aquaculture, and DNA vaccines’ advantages in cold chain and transport make them particularly appealing, making those markets important early commercial footholds. Market valuation forecasts suggest the DNA vaccine industry will grow at a roughly 6-7% compound annual growth rate over the next decade, with market size likely to double, yielding large profit potential along the entire chain—from R&D through manufacturing and distribution. However, for DNA vaccines to become mainstream there are substantial challenges. First is immunogenicity: the strength and durability of immune responses in humans, especially relative to protein-based or viral vector vaccines, remain uncertain; some candidates in early trials have not elicited sufficiently high neutralizing antibodies or lasting T cell responses. Second, regulatory approval processes are stringent; different jurisdictions impose very cautious requirements about safety, long-term effects, gene insertion risks, etc., which may lengthen time to market and raise costs. Third, cost and production complexity are high, particularly in plasmid production, purification, delivery systems, and storage/transport (including cold or semi-cold chain) steps. High standard GMP facilities and rigorous quality control are essential; any lapse can impact stability and safety. Fourth, market education and acceptance: medical practitioners, patients, and public health bodies are still learning; uncertainty around side effects or long-term outcomes may fuel hesitancy and reduce uptake. Downstream, preventive applications (for infectious diseases) remain the dominant demand, especially in regions with frequent outbreaks or under-served by existing vaccine supply. Post-COVID-19, prime-boost regimens, booster shots, and heterologous immunization strategies are giving DNA vaccines renewed interest as stable, rapidly producible complements. Therapeutic applications are growing fast: cancer vaccines, chronic viral infections (e.g. HIV, HBV/HCV), parasitic/fungal disease vaccines are under clinical or early stage research. In the veterinary sector, demand is robust in poultry, aquaculture, and livestock for DNA vaccines that reduce disease losses, antibiotic use, and enhance yield. Public health bodies and government purchasers increasingly focus on total life-cycle cost: transportation & storage infrastructure, dose volume, durability, breadth of immune coverage—all of which amplify the attractiveness of DNA vaccines that are stable, require fewer doses, and have broad immune responses. This report aims to provide a comprehensive presentation of the global market for DNA Vaccines, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of DNA Vaccines by region & country, by Type, and by Application. The DNA Vaccines market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DNA Vaccines. Market Segmentation By Company Merck GSK Sanofi Zoties Elanco Boehringer-Ingelheim Indian Immunologicals Plumbline Life Sciences Segment by Type Recombinant Protein Vaccine Gene-Based Vaccine Segment by Application Human Animal By Region North America United States Canada Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia-Pacific Europe Germany France U.K. Italy Netherlands Nordic Countries Rest of Europe Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Chapter Outline Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter 2: Detailed analysis of DNA Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Revenue of DNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world. Chapter 6: Revenue of DNA Vaccines in country level. It provides sigmate data by Type, and by Application for each country/region. Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc. Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion. Table of Contents1 Market Overview1.1 DNA Vaccines Product Introduction 1.2 Global DNA Vaccines Market Size Forecast (2020-2031) 1.3 DNA Vaccines Market Trends & Drivers 1.3.1 DNA Vaccines Industry Trends 1.3.2 DNA Vaccines Market Drivers & Opportunity 1.3.3 DNA Vaccines Market Challenges 1.3.4 DNA Vaccines Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global DNA Vaccines Players Revenue Ranking (2024) 2.2 Global DNA Vaccines Revenue by Company (2020-2025) 2.3 Key Companies DNA Vaccines Manufacturing Base Distribution and Headquarters 2.4 Key Companies DNA Vaccines Product Offered 2.5 Key Companies Time to Begin Mass Production of DNA Vaccines 2.6 DNA Vaccines Market Competitive Analysis 2.6.1 DNA Vaccines Market Concentration Rate (2020-2025) 2.6.2 Global 5 and 10 Largest Companies by DNA Vaccines Revenue in 2024 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DNA Vaccines as of 2024) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Recombinant Protein Vaccine 3.1.2 Gene-Based Vaccine 3.2 Global DNA Vaccines Sales Value by Type 3.2.1 Global DNA Vaccines Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global DNA Vaccines Sales Value, by Type (2020-2031) 3.2.3 Global DNA Vaccines Sales Value, by Type (%) (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Human 4.1.2 Animal 4.2 Global DNA Vaccines Sales Value by Application 4.2.1 Global DNA Vaccines Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global DNA Vaccines Sales Value, by Application (2020-2031) 4.2.3 Global DNA Vaccines Sales Value, by Application (%) (2020-2031) 5 Segmentation by Region 5.1 Global DNA Vaccines Sales Value by Region 5.1.1 Global DNA Vaccines Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global DNA Vaccines Sales Value by Region (2020-2025) 5.1.3 Global DNA Vaccines Sales Value by Region (2026-2031) 5.1.4 Global DNA Vaccines Sales Value by Region (%), (2020-2031) 5.2 North America 5.2.1 North America DNA Vaccines Sales Value, 2020-2031 5.2.2 North America DNA Vaccines Sales Value by Country (%), 2024 VS 2031 5.3 Europe 5.3.1 Europe DNA Vaccines Sales Value, 2020-2031 5.3.2 Europe DNA Vaccines Sales Value by Country (%), 2024 VS 2031 5.4 Asia Pacific 5.4.1 Asia Pacific DNA Vaccines Sales Value, 2020-2031 5.4.2 Asia Pacific DNA Vaccines Sales Value by Region (%), 2024 VS 2031 5.5 South America 5.5.1 South America DNA Vaccines Sales Value, 2020-2031 5.5.2 South America DNA Vaccines Sales Value by Country (%), 2024 VS 2031 5.6 Middle East & Africa 5.6.1 Middle East & Africa DNA Vaccines Sales Value, 2020-2031 5.6.2 Middle East & Africa DNA Vaccines Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions DNA Vaccines Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions DNA Vaccines Sales Value, 2020-2031 6.3 United States 6.3.1 United States DNA Vaccines Sales Value, 2020-2031 6.3.2 United States DNA Vaccines Sales Value by Type (%), 2024 VS 2031 6.3.3 United States DNA Vaccines Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe DNA Vaccines Sales Value, 2020-2031 6.4.2 Europe DNA Vaccines Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe DNA Vaccines Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China DNA Vaccines Sales Value, 2020-2031 6.5.2 China DNA Vaccines Sales Value by Type (%), 2024 VS 2031 6.5.3 China DNA Vaccines Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan DNA Vaccines Sales Value, 2020-2031 6.6.2 Japan DNA Vaccines Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan DNA Vaccines Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea DNA Vaccines Sales Value, 2020-2031 6.7.2 South Korea DNA Vaccines Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea DNA Vaccines Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia DNA Vaccines Sales Value, 2020-2031 6.8.2 Southeast Asia DNA Vaccines Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia DNA Vaccines Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India DNA Vaccines Sales Value, 2020-2031 6.9.2 India DNA Vaccines Sales Value by Type (%), 2024 VS 2031 6.9.3 India DNA Vaccines Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 Merck 7.1.1 Merck Profile 7.1.2 Merck Main Business 7.1.3 Merck DNA Vaccines Products, Services and Solutions 7.1.4 Merck DNA Vaccines Revenue (US$ Million) & (2020-2025) 7.1.5 Merck Recent Developments 7.2 GSK 7.2.1 GSK Profile 7.2.2 GSK Main Business 7.2.3 GSK DNA Vaccines Products, Services and Solutions 7.2.4 GSK DNA Vaccines Revenue (US$ Million) & (2020-2025) 7.2.5 GSK Recent Developments 7.3 Sanofi 7.3.1 Sanofi Profile 7.3.2 Sanofi Main Business 7.3.3 Sanofi DNA Vaccines Products, Services and Solutions 7.3.4 Sanofi DNA Vaccines Revenue (US$ Million) & (2020-2025) 7.3.5 Sanofi Recent Developments 7.4 Zoties 7.4.1 Zoties Profile 7.4.2 Zoties Main Business 7.4.3 Zoties DNA Vaccines Products, Services and Solutions 7.4.4 Zoties DNA Vaccines Revenue (US$ Million) & (2020-2025) 7.4.5 Zoties Recent Developments 7.5 Elanco 7.5.1 Elanco Profile 7.5.2 Elanco Main Business 7.5.3 Elanco DNA Vaccines Products, Services and Solutions 7.5.4 Elanco DNA Vaccines Revenue (US$ Million) & (2020-2025) 7.5.5 Elanco Recent Developments 7.6 Boehringer-Ingelheim 7.6.1 Boehringer-Ingelheim Profile 7.6.2 Boehringer-Ingelheim Main Business 7.6.3 Boehringer-Ingelheim DNA Vaccines Products, Services and Solutions 7.6.4 Boehringer-Ingelheim DNA Vaccines Revenue (US$ Million) & (2020-2025) 7.6.5 Boehringer-Ingelheim Recent Developments 7.7 Indian Immunologicals 7.7.1 Indian Immunologicals Profile 7.7.2 Indian Immunologicals Main Business 7.7.3 Indian Immunologicals DNA Vaccines Products, Services and Solutions 7.7.4 Indian Immunologicals DNA Vaccines Revenue (US$ Million) & (2020-2025) 7.7.5 Indian Immunologicals Recent Developments 7.8 Plumbline Life Sciences 7.8.1 Plumbline Life Sciences Profile 7.8.2 Plumbline Life Sciences Main Business 7.8.3 Plumbline Life Sciences DNA Vaccines Products, Services and Solutions 7.8.4 Plumbline Life Sciences DNA Vaccines Revenue (US$ Million) & (2020-2025) 7.8.5 Plumbline Life Sciences Recent Developments 8 Industry Chain Analysis 8.1 DNA Vaccines Industrial Chain 8.2 DNA Vaccines Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 DNA Vaccines Sales Model 8.5.2 Sales Channel 8.5.3 DNA Vaccines Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の 医薬・ヘルスケア分野 での最新刊レポート
本レポートと同じKEY WORD（dna）の最新刊レポートよくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
